You just read:

FDA Approves Eisai's LENVIMA® (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma in Combination with Everolimus Following Prior Anti-Angiogenic Therapy

News provided by

Eisai Inc.

13 May, 2016, 16:06 ET